HK1030883A1 - Preventives/remedies for glaucoma - Google Patents

Preventives/remedies for glaucoma

Info

Publication number
HK1030883A1
HK1030883A1 HK01101779A HK01101779A HK1030883A1 HK 1030883 A1 HK1030883 A1 HK 1030883A1 HK 01101779 A HK01101779 A HK 01101779A HK 01101779 A HK01101779 A HK 01101779A HK 1030883 A1 HK1030883 A1 HK 1030883A1
Authority
HK
Hong Kong
Prior art keywords
glaucoma
prophylaxis
treatment
agent
compound
Prior art date
Application number
HK01101779A
Other languages
English (en)
Inventor
Mitsuyoshi Azuma
Yukuo Yoshida
Mitsunori Waki
Masayoshi Uehata
Original Assignee
Senju Pharma Co
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co, Mitsubishi Pharma Corp filed Critical Senju Pharma Co
Priority to HK05102431.8A priority Critical patent/HK1069121A1/xx
Priority to HK05102430.9A priority patent/HK1069120A1/xx
Publication of HK1030883A1 publication Critical patent/HK1030883A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
HK01101779A 1998-08-17 2001-03-12 Preventives/remedies for glaucoma HK1030883A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
HK05102431.8A HK1069121A1 (en) 1998-08-17 2001-03-12 Agent for prophylaxis and treatment of asthenopia and pseudomyopia
HK05102430.9A HK1069120A1 (en) 1998-08-17 2001-03-12 Agent for prophylaxis and treatment of glaucoma

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP24776298 1998-08-17
JP12296099 1999-04-28
PCT/JP1999/004403 WO2000009162A1 (fr) 1998-08-17 1999-08-13 Medicaments preventifs/curatifs pour le glaucome

Publications (1)

Publication Number Publication Date
HK1030883A1 true HK1030883A1 (en) 2001-05-25

Family

ID=26459997

Family Applications (3)

Application Number Title Priority Date Filing Date
HK01101779A HK1030883A1 (en) 1998-08-17 2001-03-12 Preventives/remedies for glaucoma
HK05102430.9A HK1069120A1 (en) 1998-08-17 2001-03-12 Agent for prophylaxis and treatment of glaucoma
HK05102431.8A HK1069121A1 (en) 1998-08-17 2001-03-12 Agent for prophylaxis and treatment of asthenopia and pseudomyopia

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK05102430.9A HK1069120A1 (en) 1998-08-17 2001-03-12 Agent for prophylaxis and treatment of glaucoma
HK05102431.8A HK1069121A1 (en) 1998-08-17 2001-03-12 Agent for prophylaxis and treatment of asthenopia and pseudomyopia

Country Status (12)

Country Link
US (2) US6673812B1 (de)
EP (3) EP1459742B9 (de)
JP (2) JP3720264B2 (de)
KR (1) KR100616466B1 (de)
CN (2) CN1293878C (de)
AT (3) ATE529102T1 (de)
AU (1) AU5198199A (de)
CA (2) CA2635412C (de)
DE (1) DE69927936T2 (de)
ES (3) ES2372572T3 (de)
HK (3) HK1030883A1 (de)
WO (1) WO2000009162A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4260370B2 (ja) * 1998-08-10 2009-04-30 旭化成ファーマ株式会社 塩酸ファスジルの経口徐放性製剤
WO2000057914A1 (fr) * 1999-03-25 2000-10-05 Santen Pharmaceutical Co., Ltd. Agents permettant d'abaisser la tension oculaire
DE60036540T2 (de) * 1999-03-25 2008-07-03 Mitsubishi Tanabe Pharma Corp. Rho-kinase-inhibitoren für die vorbeugung oder behandlung von interstitieller pneumonie und pulmonaler fibrose
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
BR0114020A (pt) 2000-09-20 2003-07-22 Merck Patent Gmbh 4-amino-quinazolinas
CN101310771B (zh) * 2001-04-11 2012-08-08 千寿制药株式会社 视觉功能障碍改善剂
JP2003010158A (ja) * 2001-04-26 2003-01-14 Biochemical & Pharmacological Laboratories Inc 眼精疲労モデル、その作製方法、そのモデルを用いた評価方法およびその評価法を用いて選択された薬剤
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
CA2472619A1 (en) 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
US6924290B2 (en) 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
WO2003062227A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
AU2003257588A1 (en) * 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
AU2003269413A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
WO2004045644A1 (ja) * 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
CN100390173C (zh) * 2003-06-06 2008-05-28 旭化成制药株式会社 3环系化合物
US7160894B2 (en) * 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
EP1679308B1 (de) 2003-10-15 2013-07-24 Ube Industries, Ltd. Neues indazolderivat
US8415364B2 (en) 2003-11-26 2013-04-09 Duke University Method of preventing or treating glaucoma
WO2005079829A2 (en) * 2004-02-18 2005-09-01 Wisconsin Alumni Research Foundation Method for treating glaucoma
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
FR2868310A1 (fr) * 2004-04-02 2005-10-07 Oreal Utilisation cosmetique d'au moins un inhibiteur de la production et/ou de l'activation des rhoa kinases comme agent destine a detendre les traits et/ou decontracter la peau
CN1795196B (zh) 2004-06-03 2013-07-24 千寿制药株式会社 酰胺化合物在制备用于修复角膜敏感性的药剂中的应用
TWI367098B (en) 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
ES2368338T3 (es) * 2004-12-27 2011-11-16 Novartis Ag Análogos de aminopirazina para el tratamiento del glaucoma y otras enfermedades mediadas por la rho cinasa.
US20090029970A1 (en) * 2005-02-16 2009-01-29 Astellas Pharma Inc. Pain remedy containing rock inhibitor
JP4972551B2 (ja) * 2005-06-21 2012-07-11 興和株式会社 緑内障の予防又は治療剤
WO2007007737A1 (ja) 2005-07-12 2007-01-18 Kowa Co., Ltd. 緑内障を予防又は治療する薬剤
KR20080040027A (ko) 2005-09-02 2008-05-07 아스테라스 세이야쿠 가부시키가이샤 Ｒｏｃｋ 억제제로서 아미드 유도체
ZA200804497B (en) * 2005-12-22 2009-10-28 Alcon Res Ltd (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
CA2653424A1 (en) 2006-06-08 2007-12-13 Ube Industries, Ltd. Novel indazole derivative having spiro ring structure in side chain
BRPI0714782A2 (pt) * 2006-07-31 2013-07-16 Senju Pharma Co preparaÇço lÍquida aquosa contendo composto de amida
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
AR064420A1 (es) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
US8076332B2 (en) 2006-12-26 2011-12-13 Santen Pharmaceutical Co., Ltd. N- (2-aminophenyl) benzamide derivative having urea structure
EP2133339A4 (de) 2007-03-28 2010-04-21 Santen Pharmaceutical Co Ltd Neues (2-aminophenyl)pyridincarboxamidderivat mit harnstoffstruktur
CN101646460A (zh) 2007-03-28 2010-02-10 参天制药株式会社 含有具有组蛋白脱乙酰化酶抑制作用的化合物作为有效成分的降眼压剂
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
BRPI0816182A2 (pt) * 2007-08-29 2015-04-14 Senju Pharma Co Agente para promoção de adesão celular endotelial corneana
KR20140130725A (ko) * 2007-09-21 2014-11-11 아이진 주식회사 트롬빈 유래 펩타이드를 포함하는 망막증 또는 녹내장 치료용 조성물
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
AU2009221859B2 (en) 2008-03-05 2013-04-18 Alcon Inc. Methods and apparatus for treating glaucoma
JP2010001289A (ja) 2008-05-23 2010-01-07 Santen Pharmaceut Co Ltd ウレア構造を有する新規チオフェンジアミン誘導体
KR20110042054A (ko) 2008-07-24 2011-04-22 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 축성 근시의 예방 또는 치료제
EP2319514A4 (de) * 2008-07-25 2011-11-02 Asahi Kasei Pharma Corp Stabile wässrige lösungszusammensetzung mit einer sulfonamidverbindung
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2010032875A2 (en) * 2008-09-18 2010-03-25 Astellas Pharma Inc. Heterocyclic carboxamide compounds
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
US10272035B2 (en) * 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
US10842669B2 (en) 2008-11-13 2020-11-24 Gholam A. Peyman Ophthalmic drug delivery method
AR078033A1 (es) 2009-04-03 2011-10-12 Plexxikon Inc Una dispersion solida, que contiene al compuesto {3-[5-(4-(cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico, composiciones y formulaciones que comprenden a dicha dispersion solida; metodos para fabricar dicha dispersion solida, formas 1 y 2 de
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
AU2010271274B2 (en) 2009-07-09 2015-05-21 Alcon Inc. Single operator device for delivering an ocular implant
EP2451503B1 (de) 2009-07-09 2018-10-24 Ivantis, Inc. Augenimplantate und verfahren zur freisetzung von augenimplantaten im auge
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011021221A2 (en) 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
ES2633317T3 (es) 2009-11-06 2017-09-20 Plexxikon, Inc. Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
AU2011282887A1 (en) * 2010-07-27 2013-02-07 Inspire Pharmaceuticals, Inc. Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
ES2684351T3 (es) 2011-02-04 2018-10-02 Kowa Co., Ltd. Terapia farmacológica para prevenir o tratar glaucoma
MA34948B1 (fr) 2011-02-07 2014-03-01 Plexxikon Inc Composes et procedes de modulation de kinase, et leurs indications
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
TWI643619B (zh) * 2012-07-13 2018-12-11 日商參天製藥股份有限公司 一種用於預防或治療青光眼或高眼壓症、或降低眼壓之醫藥組合物及其用途
US10617558B2 (en) 2012-11-28 2020-04-14 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
US20160339018A1 (en) 2013-04-24 2016-11-24 Kyushu University, National University Corporation Therapeutic agent for ocular fundus disease
US10709547B2 (en) 2014-07-14 2020-07-14 Ivantis, Inc. Ocular implant delivery system and method
US9844556B2 (en) 2015-03-25 2017-12-19 Megumi Honjo Preventive/therapeutic method and preventive/therapeutic agent for complications after cataract surgery
CA2995240A1 (en) 2015-08-14 2017-02-23 Ivantis, Inc. Ocular implant with pressure sensor and delivery system
EP4088719A1 (de) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von kapillarer nichtperfusion der netzhaut
WO2017064119A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
US11938058B2 (en) 2015-12-15 2024-03-26 Alcon Inc. Ocular implant and delivery system
EP4338751A3 (de) 2017-12-21 2024-05-22 Santen Pharmaceutical Co., Ltd. Arzneimittel mit einer kombination aus sepetaprost und rho-assoziiertem coiled-coil mit einem proteinkinasehemmer
CN115038449A (zh) 2020-02-05 2022-09-09 尼科斯股份有限公司 用于治疗青光眼和眼高压的组合物
WO2022150684A1 (en) 2021-01-11 2022-07-14 Ivantis, Inc. Systems and methods for viscoelastic delivery
JP2024503021A (ja) 2021-01-11 2024-01-24 インサイト・コーポレイション Ｊａｋ経路阻害剤及びｒｏｃｋ阻害剤を含む併用療法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838677A (en) 1987-04-06 1989-06-13 Ayetech Inc. Eye exercising devices
US5250547A (en) * 1991-08-29 1993-10-05 Syntex (U.S.A.) Inc. Benzopyran derivatives
KR940702451A (ko) 1991-09-06 1994-08-20 고야 다다시 4-아미로(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
IL104755A0 (en) 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
US5618955A (en) 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
IL103932A (en) * 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
JP3066561B2 (ja) * 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
JPH07133225A (ja) 1993-11-09 1995-05-23 Santen Pharmaceut Co Ltd 毛様体筋緊張緩和剤
EP1195372A1 (de) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-Heterozyklisch substitutierte Benzamid Deriviate mit antihypertensiver Wirkung
JPH08198876A (ja) * 1995-01-30 1996-08-06 Yoshitomi Pharmaceut Ind Ltd トランス−Ｎ−（１Ｈ−ピラゾロ〔３，４−ｂ〕ピリジン−４−イル）−４−グアニジノメチルシクロヘキサンカルボキサミド・１メタンスルホン酸塩・１水和物
US5888173A (en) 1995-08-10 1999-03-30 Singhal; Tara Chand Health saver computer break
JP3421217B2 (ja) * 1995-11-20 2003-06-30 麒麟麦酒株式会社 Ｒｈｏ標的タンパク質Ｒｈｏキナーゼ
US5906819A (en) 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
JPH09143099A (ja) 1995-11-27 1997-06-03 Santen Pharmaceut Co Ltd 毛様体筋緊張緩和剤
AU720326B2 (en) 1995-12-21 2000-05-25 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
US5798380A (en) * 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
CA2263425C (en) * 1996-08-12 2008-09-30 Yoshitomi Pharmaceutical Industries Ltd. Pharmaceutical agent containing rho kinase inhibitor

Also Published As

Publication number Publication date
CN1287494A (zh) 2001-03-14
KR100616466B1 (ko) 2006-08-29
CA2307285C (en) 2009-03-31
CN1293878C (zh) 2007-01-10
ATE527993T1 (de) 2011-10-15
US20030125351A1 (en) 2003-07-03
EP1459742B1 (de) 2011-10-12
JP4490748B2 (ja) 2010-06-30
EP1459743B1 (de) 2011-10-19
CA2307285A1 (en) 2000-02-24
EP1459742A3 (de) 2007-12-26
ES2374518T3 (es) 2012-02-17
EP1459742A2 (de) 2004-09-22
EP1459743A3 (de) 2007-12-26
EP1034793A1 (de) 2000-09-13
EP1034793B1 (de) 2005-10-26
ES2247822T3 (es) 2006-03-01
US6649625B2 (en) 2003-11-18
CN1494903A (zh) 2004-05-12
CN1195547C (zh) 2005-04-06
US6673812B1 (en) 2004-01-06
CA2635412A1 (en) 2000-02-24
KR20010015761A (ko) 2001-02-26
EP1459743A2 (de) 2004-09-22
HK1069120A1 (en) 2005-05-13
HK1069121A1 (en) 2005-05-13
EP1459743A8 (de) 2005-02-02
ES2372572T3 (es) 2012-01-23
EP1459742B9 (de) 2012-05-02
ATE529102T1 (de) 2011-11-15
EP1459743B9 (de) 2012-08-01
CA2635412C (en) 2011-06-21
DE69927936D1 (de) 2005-12-01
JP2004277432A (ja) 2004-10-07
JP3720264B2 (ja) 2005-11-24
AU5198199A (en) 2000-03-06
ATE307609T1 (de) 2005-11-15
WO2000009162A1 (fr) 2000-02-24
EP1034793A4 (de) 2003-07-09
DE69927936T2 (de) 2006-06-29

Similar Documents

Publication Publication Date Title
HK1030883A1 (en) Preventives/remedies for glaucoma
HK1015691A1 (en) Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia.
AU3196900A (en) Preventives/remedies for interstitial pneumonia and pulmonary fibrosis
BR0107591A (pt) Sistemas e processos para reduzir a pressão intraocular
TWI367098B (en) Treating agent for glaucoma
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2003005941A3 (de) Insert zur behandlung des trockenen auges
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
TW200501949A (en) Ophthalmic compositions for treating ocular hypertension
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
MXPA03005922A (es) Metodo para tratar glaucoma ib.
EP1251862A4 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
HU9902097D0 (en) Method for treating glaucoma
EP1121932A4 (de) Heilmittel für augenerkrankungen
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
EP0785193A4 (de) Arylthiadiazol-derivate und diese enthaltende antivirale arzneimittel
WO2002060339A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2003101379A3 (en) Pyranoindazoles and their use for the treatment of glaucoma
WO2002096317A3 (en) Method for treating glaucoma vi
DK0946503T3 (da) Nitromethylthiobenzenderivater som inhibitorer for aldosereductase
WO2004087051A3 (en) Ophthalmic compositions for treating ocular hypertension
MX9705379A (es) Uso de los 3,4-difenil-cromanos para la fabricacion de una composicion farmaceutica para el tratamiento o profilaxis vasodilatadora.

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 27 TO JOURNAL OF : [73] SENJU PHARMACEUTICAL CO., LTD. - 5-8, HIRANOMACHI 2-CHOME CHUO-KU - OSAKA-SHI, OSAKA 541-0046 - JAPAN - MITSUBISHI PHARMA CORPORATION - 6-9, HIRANOMACHI 2-CHOME CHUO-KU - OSAKA-SHI, OSAKA 541-0046 - JAPAN - DATED 29.9.2006

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140813